Trial · NCT01705236
Results by group23
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 23
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | -1.5 | Standard Deviation 2.7 | micrometer | |
| Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Change from baseline to month 12 | -0.8 | Standard Deviation 2.4 | micrometer |
| Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Change from baseline to month 24 | -1.1 | Standard Deviation 2.4 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-superior RNFL thickness: month 12 | 0.5 | Standard Deviation 4.0 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-superior RNFL thickness: month 24 | -0.4 | Standard Deviation 3.4 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-superior RNFL thickness: month 36 | -0.7 | Standard Deviation 3.9 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-inferior RNFL thickness: month 12 | -1.2 | Standard Deviation 4.9 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-inferior RNFL thickness: month 24 | -1.6 | Standard Deviation 5.1 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Nasal-inferior RNFL thickness: month 36 | -2.1 | Standard Deviation 5.2 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-inferior RNFL thickness: month 12 | -1.2 | Standard Deviation 2.5 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-inferior RNFL thickness: month 24 | -1.6 | Standard Deviation 3.1 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-inferior RNFL thickness: month 36 | -2.3 | Standard Deviation 4.1 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-superior RNFL thickness: month 12 | -0.5 | Standard Deviation 3.9 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-superior RNFL thickness: month 24 | -0.4 | Standard Deviation 3.4 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT) | Fingolimod - Longitudinal Assessment | Temporal-superior RNFL thickness: month 36 | -1.1 | Standard Deviation 4.1 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV) | Fingolimod - Longitudinal Assessment | Change from baseline to month 12 | -0.03 | Standard Deviation 0.08 | Cubic millimeter |
| Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV) | Fingolimod - Longitudinal Assessment | Change from baseline to month 24 | -0.04 | Standard Deviation 0.08 | Cubic millimeter |
| Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV) | Fingolimod - Longitudinal Assessment | Change from baseline to month 36 | -0.06 | Standard Deviation 0.10 | Cubic millimeter |
| Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP) | Fingolimod - Longitudinal Assessment | Change from baseline to month 12 | -0.49 | Standard Deviation 2.39 | micrometer |
| Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP) | Fingolimod - Longitudinal Assessment | Change from baseline to month 24 | -0.42 | Standard Deviation 2.74 | micrometer |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01705236/results